Obicetrapib is a small molecule commercialized by NewAmsterdam Pharma Company, with a leading Phase III program in Dyslipidemia;Heterozygous familial hypercholesterolemia (heFH). According to Globaldata, it is involved in 25 clinical trials, of which 19 were completed, 4 are ongoing, 1 is planned, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Obicetrapib’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Obicetrapib is expected to reach an annual total of $254 mn by 2036 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Obicetrapib Overview
Obicetrapib calcium (AMG-899, DEZ-001, TA-8995) is under development for Alzheimer’s disease, atherosclerosis, dyslipidemia and heterozygous familial hypercholesterolemia (HeFH). It is administered orally as once daily formulation. The drug candidate acts by targeting cholesteryl ester transfer protein (CETP).
It was under development for was under development for the treatment of mild dyslipidemia by Amgen and diabetes.
NewAmsterdam Pharma Company Overview
NewAmsterdam Pharma Company (NAP), a clinical stage biotechnology company focused on the research and development of transformative therapies for cardio-renal diseases. The company is headquartered in the Netherlands.
The company reported revenues of (US Dollars) US$14.1 million for the fiscal year ended December 2023 (FY2023), a decrease of 86.3% over FY2022. The operating loss of the company was US$183 million in FY2023, compared to an operating loss of US$3.6 million in FY2022. The net loss of the company was US$176.9 million in FY2023, compared to a net loss of US$22.6 million in FY2022.
The company reported revenues of US$2.3 million for the second quarter ended June 2024, an increase of 62.7% over the previous quarter.
For a complete picture of Obicetrapib’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
